Floatz Rating
CC44/100
Confidence
Indicative
Sponsor
Oncopeptides AB
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
29Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03639610CT.gov PK of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With RRMM and Impaired Renal Function | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Kidney Failure
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Melphalan Flufenamide (this asset) | Oncopeptides AB | P2 | CC · 44 |
| Normal Human Serum Albumin | Anna Cruceta | P4 | BBB |
| Dexasone | Augusta University | P3 | BB |
| Midodrine | Anna Cruceta | P4 | BB |
| Envarsus Product | University of Alberta | P4 | BB |
| Dolutegravir | Thomas Benfield | P4 | BB |
| Bortezomib | Augusta University | P2 | BB |
| Doravirine | Thomas Benfield | P4 | BB |
| Metformin | Cairo University | P4 | BB |
+42 more in the Kidney Failure cohort
Other indications for Melphalan Flufenamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colorectal Neoplasm | — | P3 | CCC · 48 |
| Plasma Cell Myeloma | — | P3 | CC · 47 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Melphalan Flufenamide in Kidney Failure. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/melphalan-flufenamide-kidney-failure
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →